Skip to main content
. 2012 Feb 29;12:79. doi: 10.1186/1471-2407-12-79

Figure 2.

Figure 2

Distribution of DYX1C1 mRNA expression stratified by progesterone receptor status and lymph node involvement. (A) Boxplot of the distribution of DYX1C1 mRNA expression examined by qRT-PCR in the CAHRES cohort between PR-positive and PR-negative tumors. The expression of DYX1C1 is significantly higher in PR-positive tumors. Note that the y-axis is inverted, a lower dCT value indicates higher expression. (B) Boxplot of the distribution of DYX1C1 mRNA expression examined by microarray in the Uppsala cohort between PR-positive and PR-negative tumors. The expression of DYX1C1 is significantly higher in PR-positive tumors. (C) Boxplot of the distribution of DYX1C1 mRNA expression examined by qRT-PCR in the CAHRES cohort between patients with positive lymph node metastasis and negative lymph node metastasis. The expression of DYX1C1 is significantly higher in tumors of lymph node-positive patients. Note that the y-axis is inverted, a lower dCT value indicates higher expression. (D) Boxplot of the distribution of DYX1C1 mRNA expression examined by qRT-PCR in the CAHRES cohort between patients with positive and negative periglandular growth. The expression of DYX1C1 is significantly higher in patients with periglandular growth. Note that the y-axis is inverted, a lower dCT value indicates higher expression.